JP2024524613A - Ｍ６ｐｒ細胞表面受容体結合化合物及びコンジュゲート - Google Patents

Ｍ６ｐｒ細胞表面受容体結合化合物及びコンジュゲート Download PDF

Info

Publication number
JP2024524613A
JP2024524613A JP2024501118A JP2024501118A JP2024524613A JP 2024524613 A JP2024524613 A JP 2024524613A JP 2024501118 A JP2024501118 A JP 2024501118A JP 2024501118 A JP2024501118 A JP 2024501118A JP 2024524613 A JP2024524613 A JP 2024524613A
Authority
JP
Japan
Prior art keywords
optionally substituted
compound
conjugate
alkyl
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024501118A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024524613A5 (https=
Inventor
ブレット ブラッドリー ブッシュ，
ジャスティン トーマス アーンスト，
ギャリック ケー． パッカード，
ジェイソン ジー． ルイス，
エリック ディー． タートル，
Original Assignee
ライシア セラピューティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ライシア セラピューティクス， インコーポレイテッド filed Critical ライシア セラピューティクス， インコーポレイテッド
Publication of JP2024524613A publication Critical patent/JP2024524613A/ja
Publication of JP2024524613A5 publication Critical patent/JP2024524613A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/18—Acyclic radicals, substituted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2024501118A 2021-07-14 2022-07-14 Ｍ６ｐｒ細胞表面受容体結合化合物及びコンジュゲート Pending JP2024524613A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163221915P 2021-07-14 2021-07-14
US63/221,915 2021-07-14
PCT/US2022/037196 WO2023288015A1 (en) 2021-07-14 2022-07-14 M6pr cell surface receptor binding compounds and conjugates

Publications (2)

Publication Number Publication Date
JP2024524613A true JP2024524613A (ja) 2024-07-05
JP2024524613A5 JP2024524613A5 (https=) 2025-07-23

Family

ID=82786881

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024501118A Pending JP2024524613A (ja) 2021-07-14 2022-07-14 Ｍ６ｐｒ細胞表面受容体結合化合物及びコンジュゲート

Country Status (7)

Country Link
US (1) US20240335544A1 (https=)
EP (1) EP4370156A1 (https=)
JP (1) JP2024524613A (https=)
CN (1) CN117915956A (https=)
AU (1) AU2022310346A1 (https=)
CA (1) CA3226268A1 (https=)
WO (1) WO2023288015A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4370157A1 (en) 2021-07-14 2024-05-22 Lycia Therapeutics, Inc. Asgpr cell surface receptor binding compounds and conjugates
JP2026503462A (ja) 2023-01-18 2026-01-29 ライシア セラピューティクス， インコーポレイテッド 自己抗体の分解のためのリソソーム標的化二官能性分子
CN120835794A (zh) * 2023-01-18 2025-10-24 利西亚治疗公司 M6pr结合化合物和缀合物
CN120882430A (zh) 2023-01-18 2025-10-31 利西亚治疗公司 循环溶酶体靶向抗体缀合物
WO2024182772A2 (en) * 2023-03-02 2024-09-06 Avilar Therapeutics, Inc. Mannose 6-phosphate receptor binding compounds for the degradation of extracellular proteins
FR3149188A1 (fr) * 2023-05-31 2024-12-06 Nanomedsyn Pro-ligands, conjugués comprenant lesdits pro-ligands et leurs utilisations pour des applications thérapeutiques
CN121548590A (zh) * 2023-07-25 2026-02-17 深圳湾实验室 一种多特异性结合蛋白及其应用
WO2026015664A1 (en) 2024-07-10 2026-01-15 Lycia Therapeutics, Inc. Cycling lysosomal targeting chimeras targeting immunoglobulin e (ige)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
DK1791565T3 (en) 2004-09-23 2016-08-01 Genentech Inc Cysteingensplejsede antibodies and conjugates
WO2015143091A1 (en) 2014-03-19 2015-09-24 Genzyme Corporation Site-specific glycoengineering of targeting moieties
CA3205824A1 (en) 2014-10-09 2016-04-14 Genzyme Corporation Glycoengineered antibody drug conjugates
FR3041345B1 (fr) * 2015-09-18 2019-06-14 Nanomedsyn Composes polysaccharides multi-fonctionnalises et leur utilisation pour cibler le recepteur du mannose 6-phosphate cation-independant
AU2019404061A1 (en) 2018-12-19 2021-07-22 The Board Of Trustees Of The Leland Stanford Junior University Bifunctional molecules for lysosomal targeting and related compositions and methods
US20230051872A1 (en) 2019-03-22 2023-02-16 Reflexion Pharmaceuticals, Inc. Multivalent D-Peptidic Compounds for Target Proteins
KR20220044612A (ko) 2019-03-22 2022-04-08 리플렉시온 파마슈티컬스, 인크. Vegf에 대한 d-펩티드성 화합물
US20230158155A1 (en) 2020-01-10 2023-05-25 Lycia Therapeutics, Inc. Cell Surface Receptor Binding Compounds and Conjugates
EP4171658A4 (en) * 2020-06-24 2025-04-09 Lycia Therapeutics, Inc. Modified viral compositions for viral transduction
EP4171659A4 (en) * 2020-06-24 2025-04-09 Lycia Therapeutics, Inc. BIFUNCTIONAL BRIDGE COMPOSITIONS FOR VIRAL TRANSDUCTION

Also Published As

Publication number Publication date
US20240335544A1 (en) 2024-10-10
CA3226268A1 (en) 2023-01-19
CN117915956A (zh) 2024-04-19
EP4370156A1 (en) 2024-05-22
WO2023288015A1 (en) 2023-01-19
AU2022310346A1 (en) 2024-01-25

Similar Documents

Publication Publication Date Title
JP2024524613A (ja) Ｍ６ｐｒ細胞表面受容体結合化合物及びコンジュゲート
US12258332B2 (en) ASGPR cell surface receptor binding compounds and conjugates
US20230158155A1 (en) Cell Surface Receptor Binding Compounds and Conjugates
KR102713173B1 (ko) 비스-옥타하이드로페난트렌 카복스아미드 및 이의 단백질 접합체
EP3908323A2 (en) Traceless linkers and protein-conjugates thereof
CN115651056A (zh) 类固醇类化合物及其蛋白质-偶联物
DE212016000029U1 (de) Zusammensetzungen von Antikörperkonstrukt-Agonist-Konjugaten
TW202241522A (zh) 免疫刺激化合物及結合物
EP4651902A2 (en) Asgpr binding compounds and conjugates
JP2026509055A (ja) Ｍ６ｐｒ結合化合物およびコンジュゲート
JP2026503461A (ja) サイクリングリソソーム標的化抗体コンジュゲート
EA047045B1 (ru) Бис-октагидрофенантрена карбоксамиды и их белковые конъюгаты
EA046545B1 (ru) Конъюгаты циклодекстрин-белок-лекарственное средство

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250714

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250714